In January 2008, Jan Marini Skin Research suspended U.S. sales of its product, Age Intervention Eyelash Conditioner, which had been marketed as a cosmetic product that could be used to make eyelashes look longer and increase eyelash growth. The suspension came in the wake of a November 2007 seizure of approximately $2 million worth of the product by U.S. Marshals at the request of the U.S. Food and Drug Administration (“FDA”). According to the FDA, Age Intervention Eyelash Conditioner was an “unapproved and misbranded drug,” not a cosmetic. The product contained bimatoprost, an active ingredient in Lumigan®, an FDA-approved prescription drug for glaucoma that is manufactured by Allergan. (Allergan filed a related patent-infringement lawsuit against Jan Marini Skin Research in November 2007.) Eyelash growth is a reported side effect of Lumigan. See, Press Release, “Approximately $2 Million of Potentially Harmful ‘Cosmetic’ Eye Product Seized,” U.S. Food and Drug Administration, Nov. 16, 2007, available at www.fda.gov/bbs/topics/NEWS/2007/NEW01746.html; Rhonda L. Rundle, “Drug That Lengthens Eyelashes Sets Off Flutter,” The Wall Street Journal, Nov. 19, 2007, Page B1; Rhonda L. Rundle, “Jan Marini Eyelash Product Is Taken Off the U.S. Market,” The Wall Street Journal, Jan. 7, 2008, Page B7.

The seized product is just one example of a fast-growing group of products known in the cosmetics industry as “cosmeceuticals” — cosmetic products that have medicinal or drug-like benefits. The market for cosmeceuticals is huge. According to Datamonitor, the total European and U.S. market for cosmeceuticals stands at $8.2 billion. The United States is the largest cosmeceutical market, reaching $4.2 billion in 2006 after strong annual growth of 6.7% between 2001 and 2006. Similar growth is expected between 2006-2001. See “Meeting Beauty and Wellness Needs Through Cosmeceuticals: Solving Specific Beauty and Personal Care Problems for Premium Consumers,” April 4, 2007, available at www.datamonitor.com. Search for “Cosmeceuticals” to find the article.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]